We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
There’s no national shortage of the life-saving opiate antagonist naloxone — just a shortage of the free or cheap single-use vials that Pfizer has distributed by the millions since 2017. Read More
Pfizer has announced that it will transfer the rights for Phospholine Iodide (echothiophate iodide), a treatment for a rare type of glaucoma, to New York-based biotech Fera Pharmaceuticals to ensure a continued supply of the decades-old drug that the company stopped distributing in May. Read More
The Institute for Clinical and Economic Review (ICER) issued its final word on Biogen’s newly approved and very controversial $56,000-a-year Alzheimer’s drug Aduhelm (aducanumab) Thursday, and that word is “no.” Read More
In a late-stage trial, the vaccine proved to be 100 percent effective in preventing moderate and severe disease, and more than 90 percent effective at preventing symptomatic infections. Read More
Sanofi plans to spend $3.2 billion to buy clinical-stage messenger-RNA (mRNA) therapeutics company Translate Bio, deepening its holdings in the mRNA space to develop new therapeutics and vaccines. Read More